Moderna (MRNA) stock gains as the FDA issues a "balanced" view on flu shot mRNA-1010 ahead of an AdCom meeting later this ...
Ahead of a Thursday advisory panel meeting, agency scientists highlighted shortcomings in data accrued for a vaccine the FDA ...
Investor's Business Daily on MSN
Moderna surges on this surprising FDA view for its mRNA-based flu shotModerna stock surged Tuesday after documents posted ahead of a key meeting suggested the FDA would likely approve its flu ...
Ahead of an advisory committee meeting this week, FDA reviewers raised no serious efficacy or safety concerns about Moderna's ...
With a panel of outside experts set to weigh in Thursday—and with a refusal-to-file fiasco with the FDA just barely in the rearview—Moderna and its contender for the United States’ first mRNA-based ...
A new experimental MRNA flu vaccine boosts the immune system against a wide variety of flu virus strains, according to a ...
FDA said on Thursday it would hold a meeting of outside experts next month to review Moderna's experimental flu shot.
The U.S. Food and Drug Administration's staff reviewers said preliminary assessment of Moderna's flu shot data may ...
Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 9.1% in the afternoon session after investors positioned ahead ...
The US Food and Drug Administration has refused to accept an application from Moderna to review its first mRNA seasonal flu vaccine, the company said Tuesday, in another setback for the technology ...
The efficacy of flu shots is not always the same and it’s not always optimal. Some years, they can reduce the risk of illness by as little as 20% to 30%. Messenger RNA technology, or mRNA, is widely ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results